65,437 trials
Head and Neck Cancer · Mucositis Oral · Radiation Toxicity
Primary: Comparison of Number of Participants With Grade 1 or 2 Oral Mucositis (GM-CSF and SS Groups Only) — 28; 46 participants — p=0.09
Influenza
Primary: Number of Participants Reporting at Least One Solicited Injection Site or Systemic Reaction Following Vaccination With One Dose of Either Fluzone® or Fluzone® High-Dose…
Healthy · Premature Ovarian Failure
Primary: Follicle Stimulating Hormone Stimulated Serum Inhibin B Levels. — 50.7; 48.8; 96.6; 47.7 participants
Heart Failure
Primary: Median Interval Change From Baseline in Peak VO2 — 3.90 mL/kg/min
Urinary Bladder, Overactive
Primary: Proportion of Patients Reporting "Moderately" or "Markedly" Improved on the Global Response Assessment (GRA) at 36 Months as Compared to Baseline — .77 Proportion of…
Overactive Bladder
Primary: Frequency of Voids at 12 Weeks — -2.4; -2.5 Voids/day
Insomnia · Primary Insomnia · Psychophysiologic Insomnia
Primary: Sleep Latency (SL) — 1; 2; 3; 0 participants
Hypertension
Primary: Trough Seated Diastolic Blood Pressure (DBP) — -5.5; -11.8 mmHG — p=<0.0001
Halitosis
Primary: Percentage of Participants With Rosenberg Score at Indicated Time Points — 96; 74; 79; 100 percentage of participants — p=<0.001
Multiple Myeloma
Primary: Number of Participants With Response to Treatment at Day 1 of Cycle 5 — 1; 2; 2; 1 Participants
Prostate Cancer
Primary: Changes in Normal Prostate Tissue Gene Expression Between the Baseline and 3-month Biopsies in IGF -1 and COX -2 — 0.05; NA; 0.02; NA fold change
Blood Clotting
Primary: The Number of Days to First International Normalized Ratio (INR) Within Therapeutic Range — 8.3; 4.7 days
Prostatic Neoplasms
Primary: Overall Survival — 450.0; 332.0 Days — p=<0.0001
Gastric Cancer
Primary: Progression-free Survival (PFS) Time: Independent Review Committee (IRC) Assessments — 4.4; 5.6 months — p=0.3158
Leg Ulcer · Varicose Ulcer
Primary: Primary Efficacy: Cumulative Proportion of Patients Completely Healed by the End of the Treatment Period, as Judged by the Investigator's Direct Observation. — 1; 4; 3…